Efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer

Efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer

Immune checkpoint inhibitors (ICIs) are new therapeutic strategies for non-small cell lung cancer (NSCLC). We aimed to quantitatively evaluate the efficacy and safety of ICIs in NSCLC. Pubmed, Embase, Cochrane Library, and Web of Science were searched for randomized clinical trials comparing ICIs wi...

Full description

Bibliographic Details
Main Authors: Shuai Wang, Jiatao Hao, Hao Wang, Yong Fang, Lijie Tan
Format: Article
Language:English
Published: Taylor & Francis Group 2018-08-01
Series:OncoImmunology
Subjects:
lung cancer
immunotherapy
checkpoint inhibitors
pd-1
pd-l1
meta analysis
Online Access:http://dx.doi.org/10.1080/2162402X.2018.1457600

Internet

http://dx.doi.org/10.1080/2162402X.2018.1457600

Similar Items